source
- Vertex pays second-highest M&A premium as sole bidder for CrineticsVertex Pharmaceuticals emerged as the only bidder for Crinetics Pharmaceuticals, aiming to acquire the company. The bid involved a premium that ranks as the second-highest in the biopharma sector…
- Royalty Pharma pays $125M upfront for royalty stake in AstraZeneca’s ATTR drug cliramitugRoyalty Pharma has entered a deal to acquire a royalty interest in a transthyretin amyloidosis drug being developed by AstraZeneca. The agreement involves an upfront payment of $125 million to Neu…